Agilent Technologies Inc (NYSE:A) gets upgraded to Conviction-Buy by Goldman Sachs Group

Analyst Ratings For Agilent Technologies Inc (NYSE:A)

Story continues below

Today, Agilent Technologies Inc (NYSE:A) stock received an upgrade by Goldman Sachs Group from Buy to Conviction-Buy.

There are 7 Buy Ratings, 1 Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Agilent Technologies Inc (NYSE:A) is Buy with a consensus target price of $75.8750 per share, a potential 10.20% upside.

Some recent analyst ratings include

  • 9/17/2018-Agilent Technologies Inc (NYSE:A) gets upgraded to Conviction-Buy by Goldman Sachs Group
  • 5/15/2018-Agilent Technologies Inc (NYSE:A) gets upgraded to Outperform by Cowen
  • 1/18/2018-Agilent Technologies Inc (NYSE:A) had its Buy rating reiterated by Robert W. Baird with a $76.00 price target
  • 1/8/2018-Agilent Technologies Inc (NYSE:A) had its Buy rating reiterated by Barclays with a $74.00 price target


    About Agilent Technologies Inc (NYSE:A)
    Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment services; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients. The Agilent CrossLab segment offers GC and LC columns, sample preparation products, custom chemistries, and various laboratory instrument supplies; and startup, operational, training, and compliance support, as well as asset management and consultation services. The company markets its products through direct sales, electronic commerce, resellers, manufacturers' representatives, and distributors. It has collaboration with the University of Southern California Michelson Center for Convergent Bioscience. Agilent Technologies, Inc. was founded in 1999 and is headquartered in Santa Clara, California.

    Recent Trading Activity for Agilent Technologies Inc (NYSE:A)
    Shares of Agilent Technologies Inc closed the previous trading session at 68,85 −0,49 0,71 % with 1447900 shares trading hands.

    An ad to help with our costs